Exon 10 skipping in ACAT1 caused by a novel c.949G>A mutation located at an exonic splice enhancer site. 2016

Hiroki Otsuka, and Hideo Sasai, and Mina Nakama, and Yuka Aoyama, and Elsayed Abdelkreem, and Hidenori Ohnishi, and Vassiliki Konstantopoulou, and Jörn Oliver Sass, and Toshiyuki Fukao
Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu 501‑1194, Japan.

Beta-ketothiolase deficiency, also known as mitochondrial acetoacetyl-CoA thiolase (T2) deficiency, is an autosomal recessive disease caused by mutations in the acetyl‑CoA acetyltransferase 1 (ACAT1) gene. A German T2‑deficient patient that developed a severe ketoacidotic episode at the age of 11 months, was revealed to be a compound heterozygote of a previously reported null mutation, c.472A>G (p.N158D) and a novel mutation, c.949G>A (p.D317N), in ACAT1. The c.949G>A mutation was suspected to cause aberrant splicing as it is located within an exonic splicing enhancer sequence (c. 947CTGACGC) that is a potential binding site for serine/arginine‑rich splicing factor 1. A mutation in this sequence, c.951C>T, results in exon 10 skipping. A minigene construct was synthesized that included exon 9‑truncated intron 9‑exon 10‑truncated intron 10‑exon 11, and the splicing of this minigene revealed that the c.949G>A mutant construct caused exon 10 skipping in a proportion of the transcripts. Furthermore, additional substitution of G for C at the first nucleotide of exon 10 (c.941G>C) abolished the effect of the c.949G>A mutation. Transient expression analysis of the c.949G>A mutant cDNA revealed no residual T2 activity in the mutated D317N enzyme. Therefore, c.949G>A (D317N) is a pathogenic missense mutation, and diminishes the effect of an exonic splicing enhancer and causes exon 10 skipping. The present study demonstrates that a missense mutation, or even a synonymous substitution, may disrupt enzyme function by interference with splicing.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D004742 Enhancer Elements, Genetic Cis-acting DNA sequences which can increase transcription of genes. Enhancers can usually function in either orientation and at various distances from a promoter. Enhancer Elements,Enhancer Sequences,Element, Enhancer,Element, Genetic Enhancer,Elements, Enhancer,Elements, Genetic Enhancer,Enhancer Element,Enhancer Element, Genetic,Enhancer Sequence,Genetic Enhancer Element,Genetic Enhancer Elements,Sequence, Enhancer,Sequences, Enhancer
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D005091 Exons The parts of a transcript of a split GENE remaining after the INTRONS are removed. They are spliced together to become a MESSENGER RNA or other functional RNA. Mini-Exon,Exon,Mini Exon,Mini-Exons
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000101 Acetyl-CoA C-Acetyltransferase An enzyme that catalyzes the formation of acetoacetyl-CoA from two molecules of ACETYL COA. Some enzymes called thiolase or thiolase-I have referred to this activity or to the activity of ACETYL-COA C-ACYLTRANSFERASE. Acetoacetyl CoA Thiolase,Acetyl Coenzyme A Acetyltransferase,Acetyl-CoA Acetyltransferase,Acetyl CoA Acetyltransferase,Acetyl CoA C Acetyltransferase,Acetyltransferase, Acetyl-CoA,C-Acetyltransferase, Acetyl-CoA,CoA Thiolase, Acetoacetyl,Thiolase, Acetoacetyl CoA
D000102 Acetyl-CoA C-Acyltransferase Enzyme that catalyzes the final step of fatty acid oxidation in which ACETYL COA is released and the CoA ester of a fatty acid two carbons shorter is formed. 3-Ketoacyl CoA Thiolase,3-Ketothiolase,Acetyl CoA Acyltransferase,Acetyl Coenzyme A Acyltransferase,beta-Ketothiolase,2-Methylacetoacetyl CoA Thiolase,3-Oxoacyl CoA Thiolase,3-Oxoacyl-Coenzyme A Thiolase,beta-Ketoacyl Thiolase,Acetyl CoA C Acyltransferase,Acyltransferase, Acetyl CoA,C-Acyltransferase, Acetyl-CoA,CoA Acyltransferase, Acetyl,CoA Thiolase, 2-Methylacetoacetyl,CoA Thiolase, 3-Ketoacyl,CoA Thiolase, 3-Oxoacyl,Thiolase, 2-Methylacetoacetyl CoA,Thiolase, 3-Ketoacyl CoA,Thiolase, 3-Oxoacyl CoA,Thiolase, 3-Oxoacyl-Coenzyme A,Thiolase, beta-Ketoacyl,beta Ketoacyl Thiolase,beta Ketothiolase
D000592 Amino Acid Metabolism, Inborn Errors Disorders affecting amino acid metabolism. The majority of these disorders are inherited and present in the neonatal period with metabolic disturbances (e.g., ACIDOSIS) and neurologic manifestations. They are present at birth, although they may not become symptomatic until later in life. Amino Acidopathies, Congenital,Amino Acid Metabolism Disorders, Inborn,Amino Acid Metabolism, Inborn Error,Amino Acid Metabolism, Inherited Disorders,Amino Acidopathies, Inborn,Congenital Amino Acidopathies,Inborn Errors, Amino Acid Metabolism,Inherited Errors of Amino Acid Metabolism,Amino Acidopathy, Congenital,Amino Acidopathy, Inborn,Congenital Amino Acidopathy,Inborn Amino Acidopathies,Inborn Amino Acidopathy

Related Publications

Hiroki Otsuka, and Hideo Sasai, and Mina Nakama, and Yuka Aoyama, and Elsayed Abdelkreem, and Hidenori Ohnishi, and Vassiliki Konstantopoulou, and Jörn Oliver Sass, and Toshiyuki Fukao
August 2010, Molecular genetics and metabolism,
Hiroki Otsuka, and Hideo Sasai, and Mina Nakama, and Yuka Aoyama, and Elsayed Abdelkreem, and Hidenori Ohnishi, and Vassiliki Konstantopoulou, and Jörn Oliver Sass, and Toshiyuki Fukao
October 1996, Journal of lipid research,
Hiroki Otsuka, and Hideo Sasai, and Mina Nakama, and Yuka Aoyama, and Elsayed Abdelkreem, and Hidenori Ohnishi, and Vassiliki Konstantopoulou, and Jörn Oliver Sass, and Toshiyuki Fukao
June 1999, Journal of inherited metabolic disease,
Hiroki Otsuka, and Hideo Sasai, and Mina Nakama, and Yuka Aoyama, and Elsayed Abdelkreem, and Hidenori Ohnishi, and Vassiliki Konstantopoulou, and Jörn Oliver Sass, and Toshiyuki Fukao
March 1994, The Journal of clinical investigation,
Hiroki Otsuka, and Hideo Sasai, and Mina Nakama, and Yuka Aoyama, and Elsayed Abdelkreem, and Hidenori Ohnishi, and Vassiliki Konstantopoulou, and Jörn Oliver Sass, and Toshiyuki Fukao
September 2016, Ophthalmic genetics,
Hiroki Otsuka, and Hideo Sasai, and Mina Nakama, and Yuka Aoyama, and Elsayed Abdelkreem, and Hidenori Ohnishi, and Vassiliki Konstantopoulou, and Jörn Oliver Sass, and Toshiyuki Fukao
March 1991, Nucleic acids research,
Hiroki Otsuka, and Hideo Sasai, and Mina Nakama, and Yuka Aoyama, and Elsayed Abdelkreem, and Hidenori Ohnishi, and Vassiliki Konstantopoulou, and Jörn Oliver Sass, and Toshiyuki Fukao
December 2000, Genes, chromosomes & cancer,
Hiroki Otsuka, and Hideo Sasai, and Mina Nakama, and Yuka Aoyama, and Elsayed Abdelkreem, and Hidenori Ohnishi, and Vassiliki Konstantopoulou, and Jörn Oliver Sass, and Toshiyuki Fukao
June 2022, Brain & development,
Hiroki Otsuka, and Hideo Sasai, and Mina Nakama, and Yuka Aoyama, and Elsayed Abdelkreem, and Hidenori Ohnishi, and Vassiliki Konstantopoulou, and Jörn Oliver Sass, and Toshiyuki Fukao
December 2006, Japanese journal of clinical oncology,
Hiroki Otsuka, and Hideo Sasai, and Mina Nakama, and Yuka Aoyama, and Elsayed Abdelkreem, and Hidenori Ohnishi, and Vassiliki Konstantopoulou, and Jörn Oliver Sass, and Toshiyuki Fukao
January 2002, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!